The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
me change notification emails
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
Funding Opportunity Number:
Mar 02, 2010
Mar 02, 2010
Original Closing Date for Applications:
May 20, 2010
Current Closing Date for Applications:
May 20, 2010
Jun 19, 2010
Funding Instrument Type:
Category of Funding Activity:
Science and Technology and other Research and Development
Expected Number of Awards:
Estimated Total Program Funding:
Military Medical Research and Development
Cost Sharing or Matching Requirement:
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Dept. of the Army -- USAMRAA
The NFRP New Investigator Award (NIA) mechanism was first offered in FY99. Since that time, 179 NIA applications have been received, and 38 have been recommended for funding.
The intent of the NFRP NIA is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Experience in NF research is allowed, but not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. NIA proposals must include preliminary data originating from the PI, research team, or collaborator that is relevant to NF and the proposed project.
Areas of Encouragement: The FY10 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas:
• Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities;
DOD FY10 Neurofibromatosis New Investigator Award 3
• Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
• Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and
• Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF.
Research involving human subject use is permitted; however, clinical trials are NOT ALLOWED under this funding opportunity. In general, a clinical trial is defined as a prospective study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. PIs wishing to apply for funding for a clinical trial should utilize the FY10 NFRP Clinical Trial Award mechanism. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical substances.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
PA HELP: 301-619-7079; firstname.lastname@example.org
eReceipt HELP: 301-682-5507; email@example.com
CDMRP Help Desk
Synopsis Modification History
There are currently no modifications for this opportunity.